




OVERVIEW

- Developing novel therapeutics for infectious diseases, medical countermeasures and substance abuse
- Advancing use of Bucillamine for COVID-19 and companion long COVID diagnostic, and nerve agent exposure
- Clinical study with psilocybin for substance use disorder
- Robust patent portfolio (16 patents and patent applications)
- Prioritize development efforts targeting FDA regulatory incentives designations (i.e. Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease)

PRODUCT PIPELINE

Product	Indication	Stage of Development	Regulatory Status
Bucillamine (Oral Tablet)	Infectious Diseases COVID-19	Completed Phase 3	Determining next steps and international opps
Bucillamine (Oral Tablet)	Infectious Diseases Long COVID	Phase 2	IND filing for clinical study
Bucillamine	Medical Countermeasures Nerve Agent	Pre-clinical	Defence R&D Canada – Research funded by Suffield Research Centre, Canadian Department of National Defence
Oral Psilocybin (Oral Capsule)	Substance Use Disorder Methamphetamine	Phase 1/2	After study completion, to prepare for FDA end-of- Phase 2 meeting

STRATEGIC PARTNERS



EXPECTED MILESTONES

- Q2-25: Results of Bucillamine for nerve agent exposure at DRDC
- Q2-25: FDA approval of Phase 2 study for Bucillamine to treat Long COVID
- Q3-25: Complete reformulation of Bucillamine IV for future studies in infectious diseases and rare disorders
- Q3-25: Interim results for Phase 1/2 study for Psilocybin in Methamphetamine Disorder at University of Wisconsin

TEAM

Management

Michael Frank, Chairman & CEO Carmelo Marrelli, CFO Derrick Welch, Advisor

Scientific and Clinical

Dr. Kelly McKee, Dr. Arshi Kizilbash, M.D., Dr. Osnesmo Mpanju, Regulatory Affairs

Directors

Michael Frank, William Jackson, Joshua Herman, Christian Scovenna and Andrew Lindzon

CONTACT INFOMATION

Revive Therapeutics Ltd. 82 Richmond Street East Toronto, ON M5C 1P1

Tel: 1-888-901-0036
E-mail: info@revivethera.com
Website: revivethera.com

STOCK INFORMATION

Ticker:	CSE: RVV, OTCQB: RVVTF,	
ricker.	FRANKFURT: 31R	
Share Price:	\$0.025 (May 20, 2025)	
52-week High / Low:	CAD \$0.035 / \$0.005	
	418,564,269 common shares	
Shares Outstanding:	35,320,334 stock options	
	63,317,263 warrants (\$0.05 - \$0.20)	
Market Cap:	CAD ~ 10,500,000	